Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

[1]  M. Kołaczkowski,et al.  Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). , 2020, European journal of medicinal chemistry.

[2]  M. Kołaczkowski,et al.  Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates , 2020, CNS Drugs.

[3]  S. Wen,et al.  Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis , 2019, Front. Aging Neurosci..

[4]  Feng Feng,et al.  Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. , 2019, Journal of medicinal chemistry.

[5]  J. Śmieja,et al.  HBK-17, a 5-HT1A Receptor Ligand With Anxiolytic-Like Activity, Preferentially Activates ß-Arrestin Signaling , 2018, Front. Pharmacol..

[6]  J. Handzlik,et al.  Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo , 2018, Molecules.

[7]  J. Sapa,et al.  Serotonin receptors in depression and anxiety: Insights from animal studies , 2018, Life sciences.

[8]  M. Bloch,et al.  Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[9]  Yiyun Huang,et al.  Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET , 2018, The Journal of Nuclear Medicine.

[10]  M. Kołaczkowski,et al.  Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating , 2018, Metabolic Brain Disease.

[11]  M. Kołaczkowski,et al.  Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents , 2018, Journal of enzyme inhibition and medicinal chemistry.

[12]  H. Kales,et al.  Managing Behavioral and Psychological Symptoms of Dementia. , 2017, The Psychiatric clinics of North America.

[13]  A. Waszkielewicz,et al.  HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels , 2017, Behavioural Brain Research.

[14]  M. Kołaczkowski,et al.  Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. , 2017, Journal of medicinal chemistry.

[15]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[16]  T. Shamliyan,et al.  Benefits and harms of atypical antipsychotics for agitation in adults with dementia , 2017, European Neuropsychopharmacology.

[17]  M. Kołaczkowski,et al.  Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor , 2017, Front. Neurosci..

[18]  T. Rummans,et al.  Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies. , 2016, Mayo Clinic proceedings.

[19]  A. Carvalho,et al.  The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature , 2016, Psychotherapy and Psychosomatics.

[20]  S. Srinivasan,et al.  Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses , 2016, Therapeutic advances in chronic disease.

[21]  P. Llorca,et al.  Investigational drugs for treating agitation in persons with dementia , 2016, Expert opinion on investigational drugs.

[22]  K. Kulig,et al.  Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. , 2016, European journal of pharmacology.

[23]  J. Hippisley-Cox,et al.  Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database , 2016, British Medical Journal.

[24]  M. Kołaczkowski,et al.  Antipsychotic-like effects of zolpidem in Wistar rats. , 2016, European journal of pharmacology.

[25]  M. Bednarski,et al.  A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity , 2015, PloS one.

[26]  M. Kołaczkowski,et al.  Idalopirdine – a small molecule antagonist of 5-HT6 with therapeutic potential against obesity , 2015, Metabolic Brain Disease.

[27]  V. Bouet,et al.  Behavioral Neuroscience Mini Review Article Spatial Memory Deficit across Aging: Current Insights of the Role of 5-ht 7 Receptors Egocentric vs. Allocentric Spatial Strategy Shift across Aging , 2022 .

[28]  Herbert Y Meltzer,et al.  The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. , 2014, Current pharmaceutical design.

[29]  M. Campillos,et al.  Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs , 2014, Genome Medicine.

[30]  M. Kołaczkowski,et al.  Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia. , 2014, Journal of medicinal chemistry.

[31]  G. Lubec,et al.  Hippocampal monoamine receptor complex levels linked to spatial memory decline in the aging C57BL/6J , 2014, Behavioural Brain Research.

[32]  U. Hacksell,et al.  On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis , 2014, Neurochemical Research.

[33]  M. Kołaczkowski,et al.  Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

[34]  Piotr Popik,et al.  Effects of the Selective 5-HT7 Receptor Antagonist SB-269970 and Amisulpride on Ketamine-Induced Schizophrenia-like Deficits in Rats , 2013, PloS one.

[35]  H. Tsai,et al.  Association of Stroke with the Receptor-Binding Profiles of Antipsychotics—A Case-Crossover Study , 2013, Biological Psychiatry.

[36]  Marcin Feder,et al.  Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening , 2013, J. Chem. Inf. Model..

[37]  E. Mukaetova-Ladinska,et al.  Behavioral and Psychological Symptoms of Dementia , 2012, Front. Neur..

[38]  N. Herrmann,et al.  The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease , 2011, CNS neuroscience & therapeutics.

[39]  J. Hippisley-Cox,et al.  Antidepressant use and risk of adverse outcomes in older people: population based cohort study , 2011, BMJ : British Medical Journal.

[40]  I. Lucki,et al.  Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats , 2011, Psychopharmacology.

[41]  J. Hippisley-Cox,et al.  Antipsychotic drugs and risk of venous thromboembolism: nested case-control study , 2010, BMJ : British Medical Journal.

[42]  R. Morphy,et al.  Medicinal Chemistry Approaches for Multitarget Drugs , 2010 .

[43]  J. Bogers,et al.  How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins , 2009, European Psychiatry.

[44]  Liam Smeeth,et al.  Exposure to antipsychotics and risk of stroke: self controlled case series study , 2008, BMJ : British Medical Journal.

[45]  M. Millan,et al.  Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s. , 2008, European journal of pharmacology.

[46]  W. Gaebel,et al.  Side effects of atypical antipsychotics: a brief overview , 2008, World psychiatry : official journal of the World Psychiatric Association.

[47]  M. Lindquist,et al.  The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports , 2008, European Journal of Clinical Pharmacology.

[48]  Mateusz Nowak,et al.  Receptor-based pharmacophores for serotonin 5-HT7R antagonists-implications to selectivity. , 2006, Journal of medicinal chemistry.

[49]  J. John Mann,et al.  Cortical 5-HT2A Receptor Signaling Modulates Anxiety-Like Behaviors in Mice , 2006, Science.

[50]  Ethan S. Burstein,et al.  Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist , 2006, Journal of Pharmacology and Experimental Therapeutics.

[51]  D. Yew,et al.  Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients , 2006, BMC Neuroscience.

[52]  M. Beer,et al.  Aminoalkyl phenyl sulfones--a novel series of 5-HT7 receptor ligands. , 2006, Bioorganic & medicinal chemistry letters.

[53]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[54]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[55]  R. Hubbard,et al.  General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction , 2005, Heart.

[56]  B. Harrison,et al.  1-(2-Aminoethyl)-3-(arylsulfonyl)-1H-indoles as novel 5-HT6 receptor ligands. , 2004, Bioorganic & medicinal chemistry letters.

[57]  D. Geschwind,et al.  Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. , 2004, Archives of neurology.

[58]  M. Garcia-Alloza,et al.  Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease , 2004, Neuropsychopharmacology.

[59]  H. Meltzer,et al.  5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release , 2001, Journal of neurochemistry.

[60]  D. Middlemiss,et al.  Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue , 2000 .

[61]  D. Collier,et al.  5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. , 1998, Human molecular genetics.

[62]  P J Lovell,et al.  (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist. , 1998, Journal of medicinal chemistry.

[63]  S. File,et al.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat , 1986, Pharmacology Biochemistry and Behavior.

[64]  R. Porsolt,et al.  Behavioural despair in rats: a new model sensitive to antidepressant treatments. , 1978, European journal of pharmacology.

[65]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[66]  U. Albert,et al.  High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder , 2015, Psychopharmacology.

[67]  M. Cornfeldt,et al.  The preclinical antipsychotic evaluation of HRP 913, a novel benzisoxazole derivative , 1983 .